Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

Abstract The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to evaluate the role of crizotinib in rare tumors that harbored either ALK or ROS1 rearrangements. Patients with ma...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	A. S. Mansfield, Z. Wei, R. Mehra, A. T. Shaw, C. H. Lieu, P. M. Forde, A. E. Drilon, E. P. Mitchell, J. J. Wright, N. Takebe, E. Sharon, D. Hovelson, S. Tomlins, J. Zeng, K. Poorman, N. Malik, R. J. Gray, S. Li, L. M. McShane, L. V. Rubinstein, D. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O’Dwyer, A. P. Chen, K. T. Flaherty
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2022-03-01
סדרה:	npj Precision Oncology
גישה מקוונת:	https://doi.org/10.1038/s41698-022-00256-w
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!